Company Overview - Shenzhou Cell is located in Beijing Economic and Technological Development Zone and was established on April 23, 2007. The company went public on June 22, 2020. Its main business involves the research and industrialization of biopharmaceutical products for malignant tumors, autoimmune diseases, infectious diseases, and genetic diseases [1][2]. Stock Performance - As of September 10, Shenzhou Cell's stock price decreased by 2.00% to 59.66 CNY per share, with a trading volume of 1.19 billion CNY and a turnover rate of 0.44%. The total market capitalization is 26.569 billion CNY [1]. - Year-to-date, Shenzhou Cell's stock has increased by 64.67%, but it has seen a decline of 6.02% over the last five trading days and 8.30% over the last 20 days. In contrast, it has risen by 31.12% over the last 60 days [1]. Financial Performance - For the first half of 2025, Shenzhou Cell reported a revenue of 972 million CNY, a year-on-year decrease of 25.50%. The net profit attributable to the parent company was -33.771 million CNY, representing a year-on-year decrease of 126.87% [2]. Shareholder Information - As of June 30, 2025, the number of shareholders for Shenzhou Cell was 9,754, a decrease of 12.74% from the previous period. The average number of tradable shares per shareholder increased by 14.60% to 45,656 shares [2]. - Notably, new institutional shareholders include Southern CSI 500 ETF, which holds 2.7025 million shares, and China Europe Medical Health Mixed A, which holds 2.3579 million shares. Hong Kong Central Clearing Limited and China Merchants National Bio-Medical Index A have exited the top ten shareholders list [2]. Market Activity - Shenzhou Cell has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on July 4, where it recorded a net purchase of 87.5322 million CNY. The total purchases amounted to 489 million CNY, accounting for 30.04% of the total trading volume, while total sales reached 402 million CNY, making up 24.66% of the total trading volume [1]. Industry Classification - Shenzhou Cell belongs to the pharmaceutical and biological sector, specifically under the subcategory of biological products, and is associated with concepts such as biomedicine, innovative drugs, vaccines, and anti-cancer drugs [2].
神州细胞跌2.00%,成交额1.19亿元,主力资金净流出1820.38万元